|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:analysis
|
statistical analysis
survival analysis
|
|
gptkbp:analyzes
|
gptkb:Dr._John_Doe
|
|
gptkbp:business_model
|
gptkb:board_game
|
|
gptkbp:clinical_trial
|
NC T01234567
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
academic institutions
community hospitals
|
|
gptkbp:collection
|
clinical assessments
patient-reported outcomes
|
|
gptkbp:criteria
|
informed consent
other malignancies
no prior chemotherapy
pregnant or breastfeeding
|
|
gptkbp:end_date
|
2015-12-31
|
|
gptkbp:events
|
5 years
regular follow-ups
|
|
gptkbp:focuses_on
|
gptkb:healthcare_organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ECOG-ACRIN E1910
|
|
gptkbp:impact
|
guidelines for practice
advancements in treatment
|
|
gptkbp:is_protected_by
|
radiation therapy
chemotherapy
|
|
gptkbp:is_studied_in
|
open-label
|
|
gptkbp:is_tested_for
|
Phase II
|
|
gptkbp:launch_date
|
2010-01-01
|
|
gptkbp:located_in
|
multiple sites
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:participants
|
overall survival
progression-free survival
|
|
gptkbp:population
|
female patients
male patients
|
|
gptkbp:primary_source
|
treatment
|
|
gptkbp:provides_information_on
|
available upon request
|
|
gptkbp:publishes
|
peer-reviewed articles
conference presentations
|
|
gptkbp:receives_funding_from
|
federal grants
|
|
gptkbp:recorded_by
|
gptkb:theorem
|
|
gptkbp:recruitment
|
gptkb:battle
referrals
|
|
gptkbp:research
|
clinical implications
improved survival rates
significant findings
interventional
reduced recurrence rates
|
|
gptkbp:result
|
gptkb:Journal_of_Clinical_Oncology
|
|
gptkbp:side_effect
|
mild to moderate
serious adverse events
|
|
gptkbp:sponsor
|
gptkb:ECOG-ACRIN_Cancer_Research_Group
|
|
gptkbp:status
|
completed
|
|
gptkbp:student_enrollment
|
200 participants
adult patients
stage II or III breast cancer
|
|
gptkbp:year
|
2015-12-31
|
|
gptkbp:bfsParent
|
gptkb:Kymriah
|
|
gptkbp:bfsLayer
|
4
|